Is skyrizi once every 3 months?

Is Skyrizi dosed every three months?

Skyrizi is started with two initial doses four weeks apart, then continues as a single injection every 12 weeks. That schedule applies to all its approved uses: moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease. The 150 mg dose is delivered as one 150 mg injection or two 75 mg injections; the 600 mg induction dose for Crohn’s is given as three 200 mg prefilled cartridges. Patients receive the first maintenance dose 8 weeks after the last induction dose, then stay on the 12-week interval thereafter.

Can the dosing interval be changed?

No. The 12-week schedule is fixed in the prescribing information and was tested in pivotal trials; shortening or lengthening it has not been studied for safety or efficacy. If a dose is missed, patients should take it as soon as possible and then resume every 12 weeks from that point. Dose adjustments for age, weight, or kidney function are not required.

How does Skyrizi compare with other IL-23 inhibitors?

Other IL-23 inhibitors such as Tremfya and Ilumya also use every-8-week or every-12-week maintenance regimens after loading doses. Skyrizi’s 12-week interval is among the longest, which some patients and physicians cite as a convenience factor when choosing between agents. Direct head-to-head trials are limited, so comparisons rely on separate studies and real-world data.

When does Skyrizi patent protection end?

The composition-of-matter patent listed in the FDA Orange Book expires in 2034, with some method-of-use patents extending into 2035. [1] Biosimilar entry is not expected before that period, though litigation or settlements could shift the timeline.

What side effects do patients ask about most?

Injection-site reactions, upper-respiratory infections, headache, and fatigue are the most frequently reported in post-marketing data. Serious infection risk is listed in the boxed warning, but rates in long-term extension studies have remained low and comparable to placebo. Patients with a history of latent tuberculosis must complete preventive therapy before starting Skyrizi.

Who makes Skyrizi and how is it supplied?

AbbVie manufactures Skyrizi. It is supplied in single-dose prefilled syringes, pens, and cartridges at 75 mg and 150 mg strengths for subcutaneous use, plus 200 mg cartridges for the Crohn’s induction regimen. No intravenous formulation is approved.

[1] https://www.drugpatentwatch.com/drugs/skyrizi